. "1"^^ . . "5" . "Imunoterapie v posledn\u00EDch letech d\u00EDky nov\u00FDm znalostem v oblasti n\u00E1dorov\u00E9 imunity je sou\u010D\u00E1st\u00ED intenzivn\u00EDho v\u00FDzkumu jako mo\u017En\u00E1 dal\u0161\u00ED strategie protin\u00E1dorov\u00E9 l\u00E9\u010Dby. Sipuleucel-T je prvn\u00EDm a zat\u00EDm jedin\u00FDm l\u00E9\u010Div\u00FDm p\u0159\u00EDpravkem imunitn\u00ED terapie schv\u00E1len\u00FD regula\u010Dn\u00EDmi l\u00E9kov\u00FDmi agenturami v USA a v Evrop\u011B pro l\u00E9\u010Dbu asymptomatick\u00E9ho \u010Di minim\u00E1ln\u011B symptomatick\u00E9ho generalizovan\u00E9ho kastra\u010Dn\u011B-refraktern\u00EDho karcinomu prostaty. Jedn\u00E1 se o prvn\u00ED p\u0159\u00EDpravek autologn\u00ED bun\u011B\u010Dn\u00E9 terapie. Tento \u010Dl\u00E1nek d\u00E1le pod\u00E1v\u00E1 stru\u010Dn\u00FD p\u0159ehled nov\u00FDch p\u0159\u00EDstup\u016F protin\u00E1dorov\u00E9 imunoterapie v klinick\u00E9m v\u00FDvoji."@cs . . "Immunotherapy in prostate cancer"@en . "Imunoterapie a karcinom prostaty"@cs . "1"^^ . . "21038" . . . . "1213-1768" . . "RIV/00216208:11130/14:10293317!RIV15-MSM-11130___" . . "The immunotherapy based on progress in tumour immunology became a part of intensive research as a novel strategy in cancer treatment. Sipuleucel-T is the first and only medicinal product approved by the regulatory agencies in USA and Europe for the treatment of asymptomatic or minimal symptomatic castrate- refractory prostate cancer. It represents the first product of autollogous cell therapy. This article gives a brief overview about new approaches in the cancer immunotherapy in clinical development."@en . "CZ - \u010Cesk\u00E1 republika" . "[F73ABDFAC6FB]" . "11130" . . . "http://www.urologiepropraxi.cz/pdfs/uro/2014/05/02.pdf" . "3"^^ . "Imunoterapie a karcinom prostaty"@cs . "Imunoterapie a karcinom prostaty" . "Imunoterapie v posledn\u00EDch letech d\u00EDky nov\u00FDm znalostem v oblasti n\u00E1dorov\u00E9 imunity je sou\u010D\u00E1st\u00ED intenzivn\u00EDho v\u00FDzkumu jako mo\u017En\u00E1 dal\u0161\u00ED strategie protin\u00E1dorov\u00E9 l\u00E9\u010Dby. Sipuleucel-T je prvn\u00EDm a zat\u00EDm jedin\u00FDm l\u00E9\u010Div\u00FDm p\u0159\u00EDpravkem imunitn\u00ED terapie schv\u00E1len\u00FD regula\u010Dn\u00EDmi l\u00E9kov\u00FDmi agenturami v USA a v Evrop\u011B pro l\u00E9\u010Dbu asymptomatick\u00E9ho \u010Di minim\u00E1ln\u011B symptomatick\u00E9ho generalizovan\u00E9ho kastra\u010Dn\u011B-refraktern\u00EDho karcinomu prostaty. Jedn\u00E1 se o prvn\u00ED p\u0159\u00EDpravek autologn\u00ED bun\u011B\u010Dn\u00E9 terapie. Tento \u010Dl\u00E1nek d\u00E1le pod\u00E1v\u00E1 stru\u010Dn\u00FD p\u0159ehled nov\u00FDch p\u0159\u00EDstup\u016F protin\u00E1dorov\u00E9 imunoterapie v klinick\u00E9m v\u00FDvoji." . "Imunoterapie a karcinom prostaty" . . . "I" . "Immunotherapy in prostate cancer"@en . . "RIV/00216208:11130/14:10293317" . "Urologie pro praxi" . "15" . "Kub\u00E1\u010Dkov\u00E1, Kate\u0159ina" . . "cancer vaccines; immunotherapy; tumour immunology; prostate carcinoma"@en .